CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics, Inc. Securities Lawsuit - Contact The Gross Law Firm

Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: December 17, 2025 to July 29, 2026 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for it's lead product candidate, Deramiocel; (2) the FDA had not agreed to those changes before the Company resubmitted the Deramiocel BLA; (3) as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; (4) as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. DEADLINE: September 28, 2026 Shareholders should not delay in registering for this class action.